Chemoprevention has the potential to be a major component of the control of colon cancer, one of the commonest malignancies. Although traditional non-steroidal anti-inflammatory drugs (NSAIDs) prevent colon cancer, their side effects are a major obstacle to their large-scale application to prevent colon cancer. The novel nitric oxide (NO)-releasing NSAIDs (NO-NSAIDs), consisting of a NSAID molecule and a NO-releasing moiety linked to it via a chemical spacer, have been synthesized to overcome NSAID toxicity. Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions. That NO-ASAs have superior effectiveness and safety makes them promising chemopreventive agents and constitutes a compelling argument to study their mechanism of action in colon carcinogenesis. The proposed studies will evaluate two hypotheses: a) NO-ASA compounds share with traditional NSAIDs some of their known mechanisms of action, such as their effects on cell kinetics and on the eicosanoid and NO pathways, all relevant to chemoprevention, and b) Since NO-ASA derivatives are markedly more effective than unmodified ASA, the additions to the ASA molecule to generate NO-ASA impart on it new properties, which make it more effective.
Our specific aims are 1) Determine in cultured colon cancer cells the effect of NO-ASA derivatives on cell kinetics (proliferation, apoptosis) and cell cycle; on the eicosanoid pathway (effect on the catalytic activity of COX; COX-1 and -2 expression and regulation; evidence for effects beyond COX); and on the nitric oxide pathway (expression of NOS isoforms; NOS catalytic activity). 2) Determine in an animal model of colon cancer the contribution of the NO-ASA-induced changes to colon carcinogenesis. Based on results from Specific Aim #1, we will select the most promising of the three NO-ASA derivatives and assess its chemopreventive efficacy against azoxymethane-induced colon carcinogenesis in F344 rats. The effect of this compound on cell kinetics and on the two metabolic pathways will be assessed and correlated with chemopreventive efficacy. 3) Assess the contribution of the key structural components of the NO-ASA molecule to their chemopreventive actions. We will study the effects of synthetic molecules representing the structural components of each one of the three NO-ASA compounds. They include: ASA+spacer (NO- ASA without the -NO2 group) to test the contribution of NO; spacer (the part linking ASA to -NO2) to test its individual contribution; and a NO-donor which releases NO, to further test the role of NO. The long-term goal of these studies is to develop mechanism-driven safe and effective strategies for colon cancer prevention.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-RAD (03))
Program Officer
Crowell, James A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Institute for Cancer Prevention
United States
Zip Code
Mackenzie, Gerardo G; Huang, Liqun; Alston, Ninche et al. (2013) Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. PLoS One 8:e61532
Wong, Chi C; Cheng, Ka-Wing; Xie, Gang et al. (2012) Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity. J Pharmacol Exp Ther 340:422-32
Ouyang, Nengtai; Zhu, Caihua; Zhou, Dingying et al. (2012) MC-12, an annexin A1-based peptide, is effective in the treatment of experimental colitis. PLoS One 7:e41585
Zhu, Rongrong; Cheng, Ka-Wing; Mackenzie, Gerardo et al. (2012) Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles. Pharm Res 29:3090-101
Cheng, Ka Wing; Mattheolabakis, George; Wong, Chi C et al. (2012) Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer. Int J Oncol 41:1199-203
Wong, C C; Cheng, Ka-Wing; Rigas, Basil (2012) Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. J Pharmacol Exp Ther 341:572-8
Sun, Yu; Huang, Liqun; Mackenzie, Gerardo G et al. (2011) Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents. J Pharmacol Exp Ther 338:775-83
Joseph, Stancy; Nie, Ting; Huang, Liqun et al. (2011) Structure-activity relationship study of novel anticancer aspirin-based compounds. Mol Med Rep 4:891-9
Zhang, Zhiquan; Huang, Liqun; Zhao, Wenping et al. (2010) Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. Cancer Res 70:2379-88
Foreman, Jennifer E; Sorg, Joseph M; McGinnis, Kathleen S et al. (2009) Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs. Mol Carcinog 48:942-52

Showing the most recent 10 out of 45 publications